TY - JOUR
T1 - Seprafilm® adhesion barrier
T2 - (2) A review of the clinical literature on intraabdominal use
AU - Diamond, Michael P.
AU - Burns, Ellen L.
AU - Accomando, Beverly
AU - Mian, Sadiqa
AU - Holmdahl, Lena
PY - 2012/9
Y1 - 2012/9
N2 - This study seeks to provide a review of the clinical data published as of July 2011 concerning the postsurgical adhesion barrier, Seprafilm (chemically modified hyaluronic acid and carboxymethylcelulose; Genzyme Corporation, Cambridge, MA). Included articles detail the application of Seprafilm for intraabdominal uses that have been approved (on-label) and those considered investigational (off-label) by the FDA. Medline and EMBASE Drugs and Pharmaceuticals databases were searched for all original clinical Seprafilm research published as of July 2011. All human Seprafilm intraabdominal clinical reports and studies, excluding those related to prosthetic mesh were included. Data extraction involved the systematic review of each article. The data synthesis is the summary of Seprafilm human intraabdominal clinical reports and studies describing safety and/or efficacy. The safety and efficacy of Seprafilm in reducing postoperative adhesions has been clearly demonstrated in abdominal and pelvic laparotomy. While reports have described the safe and successful use of Seprafilmfollowing laparoscopy, pediatric laparotomy, and in patients with malignancy and/or infection, the safety and efficacy of Seprafilm use in these procedures has not been definitively established in randomized controlled trials.
AB - This study seeks to provide a review of the clinical data published as of July 2011 concerning the postsurgical adhesion barrier, Seprafilm (chemically modified hyaluronic acid and carboxymethylcelulose; Genzyme Corporation, Cambridge, MA). Included articles detail the application of Seprafilm for intraabdominal uses that have been approved (on-label) and those considered investigational (off-label) by the FDA. Medline and EMBASE Drugs and Pharmaceuticals databases were searched for all original clinical Seprafilm research published as of July 2011. All human Seprafilm intraabdominal clinical reports and studies, excluding those related to prosthetic mesh were included. Data extraction involved the systematic review of each article. The data synthesis is the summary of Seprafilm human intraabdominal clinical reports and studies describing safety and/or efficacy. The safety and efficacy of Seprafilm in reducing postoperative adhesions has been clearly demonstrated in abdominal and pelvic laparotomy. While reports have described the safe and successful use of Seprafilmfollowing laparoscopy, pediatric laparotomy, and in patients with malignancy and/or infection, the safety and efficacy of Seprafilm use in these procedures has not been definitively established in randomized controlled trials.
KW - Adhesiolysis
KW - Anti-adhesion adjuvant
KW - Postoperative adhesions
KW - Seprafilm
UR - http://www.scopus.com/inward/record.url?scp=84865965960&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84865965960&partnerID=8YFLogxK
U2 - 10.1007/s10397-012-0742-8
DO - 10.1007/s10397-012-0742-8
M3 - Review article
AN - SCOPUS:84865965960
SN - 1613-2076
VL - 9
SP - 247
EP - 257
JO - Gynecological Surgery
JF - Gynecological Surgery
IS - 3
ER -